For BRCA1/2-related and BRCAWT patients with ovarian cancer brain metastasis treated with olaparib or niraparib as maintenance therapy, PFS ranged from 9 months to 4 years [155,156]. Here, BRCA1 is linked to ovarian carcinoma.